-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Makes Its Debut at the 23rd China International API Expo
Category:
发布时间：2025-06-26
【概要描述】
On June 24, the 23rd CPhI China 2025—the World Pharmaceutical Ingredients Exhibition—grandly opened at the Shanghai New International Expo Center in Pudong. Shijiazhuang Sihua Pharmaceutical Group’s subsidiaries, Guangxiang Pharmaceutical, Guolong Pharmaceutical, and Bosheng Medical Devices, showcased a joint exhibit, presenting a systematic product portfolio and multifaceted innovation achievements to comprehensively highlight the group’s strategic positioning and technological prowess in the API and pharmaceutical packaging materials sectors.
On June 24, the 23rd CPhI China 2025—the World Pharmaceutical Ingredients Exhibition—kicked off with great fanfare at the Shanghai New International Expo Center in Pudong. Shijiazhuang Sihua Pharmaceutical Group’s subsidiaries, Guangxiang Pharmaceutical, Guolong Pharmaceutical, and Bosheng Medical Devices, showcased their offerings as a group, presenting a systematic product portfolio and multifaceted innovations that comprehensively highlight the Group’s strategic positioning and technological prowess in the API and pharmaceutical packaging materials sectors.
As a leading industry benchmark, the China International Pharmaceutical Ingredients Exhibition is widely recognized by companies across the value chain for its distinctive hallmarks of specialization, internationalization, and high-end positioning. This event covers core segments such as pharmaceutical ingredients, natural extracts, biotechnology, and pharmaceutical excipients, bringing together numerous premium global suppliers and professional visitors from both domestic and international markets. It serves as an indispensable platform for expert networking and business collaboration within the industry ecosystem.
Inside the API exhibition hall, crowds thronged and visitors abounded. At the group’s meticulously designed and specially constructed booth, a striking and eye-catching lightbox poster proclaiming “Guangxiang Pharmaceutical’s Caffeine Has Obtained EU CEP Certification” drew the attention and footsteps of numerous business delegates and industry professionals. During the show, the group prominently showcased nearly 80 high-potential and distinctive APIs, including caffeine, azithromycin, theophylline, doxofylline, aminophylline, metronidazole, theobromine, pentoxifylline, moxifloxacin, and others, alongside complementary finished dosage forms such as soft-packaged infusions, aqueous injections, and tablets. This comprehensive display highlighted the remarkable achievements of the group’s integrated “API-plus-formulation” development strategy, fully demonstrating its dynamic momentum and vibrant vitality as it embarks on a journey of innovation and sustainability.
“The attainment of EU regulatory approval for caffeine is a testament to our robust quality management and superior product quality,” said a member of the Group’s API export team. Guided by innovation, the team has intensified efforts in developing innovative APIs and securing internationally recognized certifications, thereby advancing its global business strategy and accelerating its international expansion. This strategic move has created greater opportunities and greater certainty for identifying new growth drivers and diversifying business lines. In addition, the successful acquisition of key international certifications—including Japan’s PMDA, BRC, FSSC 22000, KOSHER, and HALAL—has further strengthened the momentum behind the company’s global market penetration.
At the Bosheng Medical Devices booth, three flagship product lines—rubber stoppers, co-extruded films, and biopharmaceutical-grade films—drew exceptional attention, attracting a steady stream of both new and existing customers. According to the company’s marketing director, the rubber stopper series has successfully obtained DMF registration with the U.S. FDA; the multi-layer co-extruded single-use biopharmaceutical films outperform comparable imported products in performance; and the infusion tubing has achieved its first-ever export to overseas markets, underscoring the company’s ongoing innovation-driven competitive edge. “We will continue to accelerate technological advancement and digital transformation, turning our innovative strengths into sustainable growth and market advantages,” the executive stated.
On the first day of the exhibition, the Group seized the opportunity to engage in in-depth business exchanges and negotiations with both new and existing domestic and international customers, striving to achieve more than half of its annual targets. According to the Group’s leadership, the exhibition will be leveraged to gain a thorough understanding of current market conditions and emerging demand trends, while actively expanding its base of high-quality clients. Moving forward, the Group will continue to promote its “going global” strategy, establish new, streamlined channels for green overseas expansion, enhance brand appeal and product influence, accelerate integration into broader international markets, elevate its level of international operations, and continuously drive the Group’s high-quality development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091